MedTrace Logo

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

NCT03781258 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-04

No results posted yet for this study

Summary

The purpose of this prospective controlled study is to obtain a multi-center safety and feasibility data on patients managed with anti-thrombotic monotherapy with HeartMate 3 LVAS.

Conditions

Interventions

DRUG

Warfarin

Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-23
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03781258 on ClinicalTrials.gov